NICE decides against costly Celgene drug; Obama calls for 'up or down vote' on reform;

  @FiercePharma: Astellas CEO: A logical idealist. Report | Follow @FiercePharma

> Britain's healthcare cost agency has recommended that Celgene's drug Vidaza, or azacitidine, should not be used in the state-run health service to treat a rare blood cancer because it is too expensive. Report

> President Barack Obama has taken command of one final attempt by Democrats to enact bitterly contested healthcare legislation, calling for an "up or down vote" within weeks. Report

> House Democratic leaders are pushing for a final vote on far-reaching health legislation in the next three weeks, aiming to answer President Barack Obama's call for swift action. Report

> Results of a trial of Pfizer's Prevnar 7 vaccine against a major cause of pneumonia and meningitis showed that it can prevent three out of four cases of re-infection in HIV-infected adults in Africa. Report

> Danish drugmaker Lundbeck posted a smaller rise in operating profits than expected and forecast higher profits this year than in 2009. Report

> A large-scale comparative test of three anti-epilepsy drugs found the oldest was best for treating childhood absence epilepsy, in which youngsters often stare into space for up to 20 seconds many times a day. Report

> When it comes to gastrointestinal side effects, not all painkillers known as non-steroidal anti-inflammatory drugs are created equal. Report

Biotech News

 @FierceBiotech: Pharma reports 26,000 layoffs in 2010. Report | Follow @FierceBiotech

 @JohnCFierce: Archimedes CEO tells me he's looking to build small, 50-100, US sales force for PecFent. Article | Follow @JohnCFierce

> An experimental vaccine being studied at the University of Nebraska Medical Center successfully spurred the development of dopamine-producing nerve cells, reversing the disease in mice. Story

> The San Francisco start-up Vaxart has banked a $12.5 million Series B venture round, with the money going to support its work building a portfolio of orally-delivered vaccines. Report

> Merck KGaA to restructure U.S. operations after Millipore buyout. Item

> New Provenge data confirms 3-year survival benefit. Story

> Sanofi-Aventis has pulled the curtain back on a slate of promising, late-stage data for its prostate cancer drug cabazitaxel, demonstrating that the therapy prolongs the life of men with advanced tumors. Article

Manufacturing News

> Pfizer takes on counterfeiters. Story

> Orphanage to boast high-containment lab. Item

> The U.S. Centers for Disease Control & Prevention has chosen Sentry BioPharma Services to store and distribute influenza vaccine for the national strategic reserve. Article

Vaccines News

> Experts ponder why regular flu season is a no-show. Story

> Professor's new chip delivers vaccines without the pain. Item

> Study: Parents need to be better informed about vaccines. Report

And Finally... A genetic test may soon help overweight people predict which diet would work best for them. Report